Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schofield, Darren J., Percival-Alwyn, Jennifer, Rytelewski, Mateusz, Hood, John, Rothstein, Raymond, Wetzel, Leslie, McGlinchey, Kelly, Adjei, Grace, Watkins, Amanda, Machiesky, LeeAnn, Chen, Weimin, Andrews, John, Groves, Maria, Morrow, Michelle, Stewart, Ross A., Leinster, Andrew, Wilkinson, Robert W., Hammond, Scott A., Luheshi, Nadia, Dobson, Claire, Oberst, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831362/
https://www.ncbi.nlm.nih.gov/pubmed/33397194
http://dx.doi.org/10.1080/19420862.2020.1857100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831362/
https://www.ncbi.nlm.nih.gov/pubmed/33397194
http://dx.doi.org/10.1080/19420862.2020.1857100

Ejemplares similares